Search results
Understanding CAR T-cell therapy: A conversation with Northside’s Dr. Melhem Solh - Atlanta Business...
The Business Journals· 6 days agoDr. Melhem Solh, medical director of the cellular therapy program at Northside Hospital, answers...
Health Beat: Do the benefits of CAR T-Cell therapy outweigh the risks?
WFMZ Eastern Pennsylvania and Western New Jersey· 5 days agoIn 2017, the FDA approved the first CAR T-cell therapy. Medical experts call it a "breakthrough" and...
India Has Low-Cost CAR T-Cell Therapy: Can US Follow Suit?
Medscape· 3 days agoDr Maurie Markman discusses a news report on decreasing the cost of CAR-T therapy and the potential...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 7 days ago-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous ...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 6 days agoIN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies, presented encouraging preliminary ...
UC San Diego Health First in Region to Provide Nov | Newswise
Newswise· 5 days agoThe personalized cellular therapy derived from tumor infiltrating lymphocytes (TIL), is the first...
Adicet Bio gains FDA Fast Track for lupus nephritis treatment By Investing.com
Investing.com· 4 days agoAdministration (FDA) has granted Fast Track Designation to their investigational therapy ADI-001,...
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders
Tehachapi News· 6 days agoPoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients ...
Tip Sheet: Breast cancer guidelines change again, | Newswise
Newswise· 4 days agoBelow are summaries of recent Fred Hutchinson Cancer Center research findings and other news. March is Colorectal Cancer Awareness Month, contact our media
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel...
Digital Journal· 6 days agoOverall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysisInterim analysis data reinforces ...